LENZ Therapeutics

IPO

Striving to restore vision

Public · Burlingame, United States · Founded 2013 · $160.5M raised

Employees
51–200
Founded
2013
Business Model
B2C
Total Funding
$160.5M
Last Round
$30.0M Private EquityJul 2024
Rounds
3
Type
Public

About

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. The lead program aims to restore near vision with a once-daily drop for a condition that impacts 128 million people in the United States.

Summary

LENZ Therapeutics is a Biotech company based in Burlingame, United States, founded in 2013. It has raised $160.5M in total across 3 rounds, most recently a $30.0M Private Equity round in Jul 2024. Investors include Ridgeback Capital, Sectoral Asset Management and Versant Ventures.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityJul 2024
$30.0M

Sign up to see all 4 rounds

Series A through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

LENZ Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/lenz-therapeutics"><img src="https://indexed.vc/api/badge/company/lenz-therapeutics" alt="LENZ Therapeutics on Indexed.vc" width="260" height="76" /></a>